Table 1 Characteristics of patients with... | American Society of Hematology

Table 1

Characteristics of patients with MCL

Patient	Age, y/sex	Disease status	Tumor cells, %*	P53 status†	Bz LC₅₀ at 24 h, nM	IPI-504 GI₅₀ at 72 h, μM
MCL no.1	64/M	Relapse	95	del/mut	Not reached	25.3 ± 0.1
MCL no.2	56/M	Diagnosis	80	wt	15.5 ± 0.2	2.9 ± 0.01
MCL no.3	83/F	Diagnosis	95	del/mut	263.1 ± 1.5	16.8 ± 0.2
MCL no.4	79/M	Diagnosis	95	wt	7.7 ± 0.7	0.7 ± 0.01
MCL no.5	76/M	Diagnosis	83	wt	236.2 ± 5.1	19.5 ± 0.04
MCL no.6	85/M	Diagnosis	85	wt	0.33 ± 0.1	1.7 ± 0.02
MCL no.7	69/M	Relapse	89	del/mut	34.1 ± 1.3	0.1 ± 0.01
MCL no.8	78/F	Diagnosis	97	wt	6.6 ± 0.5	Not reached
MCL no.9	83/M	Relapse	89	wt	17.8 ± 0.9	1.2 ± 0.05
MCL no.10	37/M	Diagnosis	86	wt	21.8 ± 1.2	0.1 ± 0.03

Patient	Age, y/sex	Disease status	Tumor cells, %*	P53 status†	Bz LC₅₀ at 24 h, nM	IPI-504 GI₅₀ at 72 h, μM
MCL no.1	64/M	Relapse	95	del/mut	Not reached	25.3 ± 0.1
MCL no.2	56/M	Diagnosis	80	wt	15.5 ± 0.2	2.9 ± 0.01
MCL no.3	83/F	Diagnosis	95	del/mut	263.1 ± 1.5	16.8 ± 0.2
MCL no.4	79/M	Diagnosis	95	wt	7.7 ± 0.7	0.7 ± 0.01
MCL no.5	76/M	Diagnosis	83	wt	236.2 ± 5.1	19.5 ± 0.04
MCL no.6	85/M	Diagnosis	85	wt	0.33 ± 0.1	1.7 ± 0.02
MCL no.7	69/M	Relapse	89	del/mut	34.1 ± 1.3	0.1 ± 0.01
MCL no.8	78/F	Diagnosis	97	wt	6.6 ± 0.5	Not reached
MCL no.9	83/M	Relapse	89	wt	17.8 ± 0.9	1.2 ± 0.05
MCL no.10	37/M	Diagnosis	86	wt	21.8 ± 1.2	0.1 ± 0.03

Del indicates deleted; mut, mutated; wt, wild-type; and Bz, bortezomib.

CD19⁺ tumor cells quantified by flow cytometry.

Assessed by fluorescent in situ hybridization and direct sequencing.